Simón Kawa Karasik explained that given the vulnerability presented by patients with Covid, greater attention and care are required in the treatments carried out. Photo: Special
–
–
MEXICO CITY.
Simón Kawa Karasik, director general of the Coordination of National Institutes of Health (CINS), presented this Sunday a list of medicines that should not be used to treat Covid-19.
Kawa Karasik explained that due to the vulnerability presented by patients with Covid, greater attention and care are required in the treatments carried out.
“We seek in all the processes that there is rapidity that there is advance planning with procedures adjusted to the urgency, but that does not mean that because it is an urgency we are going to skip all the careful methodological part or we are going to avoid some ethical questions because we are an emergency; on the contrary, ”he explained.
Therefore, Kawa Karasik detailed the protocols that have been carried out by the Ministry of Health in the units coordinated by the Coordinating Commission, among which are: Hydroxychloroquine, Tocilizumab, Remdesivir / Baricitinib, Convalescent Plasma, Favipiravir, Favipiravir + Maraviroc, Maraviroc.
Remdesivir
- Studies with Remdesivir, which is an antiviral, showed that it shortened recovery time (15 vs. 11 days) in adults hospitalized with Covid-19, but did not reduce mortality.
Tocilizumab
- Results just released less than four days ago from a phase three study show that this drug showed no clinical benefit in people with severe Covid-19 pneumonia.
Remdesivir / Baricitinib
- Remdesivir / Baricitinib which is used to help mediate, apart from the virus response, the immune response of the infected person, a controlled clinical study is currently being carried out in which 68 patients have been recruited, but the results they will be known until the study is completed and we can do the analyzes to compare the patients.
Convalescent plasma
- In the convalescent plasma study samples are taken from patients who were infected with SARS-CoV-2, who had Covid-19 disease and the antibodies are extracted from that plasma, the antibodies are looked for and tests are done to see if Antibodies, obtained from that plasma from those patients, have the ability in laboratory studies to neutralize the virus by inhibiting viral activity.
- Therefore, a multicenter, randomized controlled clinical trial is carried out in cases of severe Covid-19 disease. The ability to determine neutralizing type antibodies in donor plasma is evaluated.
Favipiravir
- Another study is conducted with Favipiravir, this is a multicenter clinical trial to determine if it stops disease progression and prevents mechanical ventilation (intubation).
Favipiravir + Maraviroc
- Another study is testing Favipiravir together with another drug that is Maraviroc, a drug that has the ability to modulate the immune response in such a way that at the same time that it is giving an antivirual, to try to decrease the ability to cause Damage from the virus, on the other hand, an immuno-modulator is being given to try to reduce the inflammatory response that infected people have.
Hidroxicloroquina
- As for Hydroxychloroquine, there is no evidence of its clinical benefits that justify its use, so it should not be used in the treatment for patients with Covid-19.
Given the above, these are the practices and medications that are not recommended against Covid-19:
- Stem cell therapy
- Chlorine dioxide
- Ivermectina
- Nitazoxamida
- Azitromizina
- Ozeltamivir
- Hidroxicloroquina
- Tocilizumab
As well as any medication outside its therapeutic indications that has not been tested through controlled clinical trials and whose results have been published publicly and through peer review to the scientific community to evaluate the results of those studies.
jcp
Copyright law strictly forbids copying Excélsior materials in whole or in part without prior written permission and without including the link to the original text.
–
